Dantrolene low-volume - Eagle Pharmaceuticals

Drug Profile

Dantrolene low-volume - Eagle Pharmaceuticals

Alternative Names: Dantrolene; Dantrolene sodium; EP-4104; Ryanodex

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Lyotropic Therapeutics
  • Developer Eagle Pharmaceuticals
  • Class Antispastics; Furans; Hydantoins; Imidazolidines; Muscle relaxants; Nitrophenols; Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wounds; Fever
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Wounds
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever
  • Preregistration Wounds

Most Recent Events

  • 14 Dec 2016 Pharmacodynamics data from a preclinical trial in Stroke released by Eagle Pharmaceuticals
  • 11 Nov 2016 Preregistration for Wounds (Exertional heat stroke) in USA (IV-injection)
  • 31 Oct 2016 Interim pharmacodynamics data from a preclinical trial in Fever released by Eagle Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top